Fig. 3From: De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysisCumulative incidence curves for the stage I–II GNEC patients in overall patients and subgroups after PSM. Overall patients (A), stage I (B), stage II (C), grade II (D), grade III/IV (E), tumor size ≤ 2 cm (F), 2 cm < tumor size ≤ 5 cm (G), SCNEC (H), LCNEC (I)Back to article page